Genpharmasec Ltd
Fundamental Score
Genpharmasec Ltd Share Price Live NSE/BSE
Profitability Metrics
Return on Equity
Return on Capital Employed
Operating Profit Margin (5Y)
Dividend Yield
Valuation Metrics
Price to Earnings
Market Capitalization
Industry P/E
Growth Metrics
YoY Quarterly Profit Growth
YoY Quarterly Sales Growth
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Financial Health
Debt to Equity
Interest Coverage
Free Cash Flow (5Y)
Ownership Structure
Promoter Holding
FII Holding
DII Holding
Pledged Percentage
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Market Data Analysis & Educational Insights
Educational evaluation of GENPHARMA across key market metrics for learning purposes.
Positive Indicators
3 factors identified
Strong Revenue Growth (441.29%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential. This indicates business expansion success.
Conservative Debt Levels (D/E: 0.17)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns and flexibility for growth investments.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral, reducing forced-selling risk.
Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.
Risk Factors
10 factors identified
Below-Average Return on Equity (1.90%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (3.35%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation. Review business model and competitive positioning.
Premium Valuation Risk (P/E: 149.01x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations. Consider entry timing carefully.
Profit Decline Concern (-268.57%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes. Monitor for recovery signs and management guidance.
Low Promoter Commitment (29.98%)
Observation: Reduced promoter stake may indicate limited confidence.
Analysis: Low promoter holding may raise questions about management commitment and long-term vision alignment.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints. Assess capital allocation strategy.
Very Low ROE
Observation: Poor capital utilization and shareholder returns.
Analysis: ROE below 5% suggests significant inefficiencies in capital deployment.
High P/E Ratio
Observation: Stock may be overvalued relative to earnings.
Analysis: P/E above 30 requires strong growth execution to justify current valuations.
Very High P/E Ratio
Observation: Significant overvaluation risk present.
Analysis: Extremely high P/E ratios indicate potential bubble territory and high downside risk.
Small Market Cap
Observation: Higher investment risk due to limited size.
Analysis: Small-cap stocks typically carry higher volatility and liquidity risks.
Financial Statements
Comprehensive financial data for Genpharmasec Ltd
About GENPHARMA
Business Overview
Genpharmasec Limited buys, sells, and distributes pharmaceutical activities and services in India. The company operates through two segments, Diagnostic Pharma Equipment, and Investment and Trading in Securities. The Diagnostic Pharma Equipment segment distributes state-of-the-art diagnostic equipment comprising of i-STAT analyzers and its cartridges used to analyze blood for test results in Intensive Care Units (ICUs) of hospitals. The Investment and Trading in Securities segment operates in secondary securities market. The company was formerly known as Generic Pharmasec Limited and changed its name to Genpharmasec Limited in October 2021. Genpharmasec Limited was incorporated in 1992 and is based in Mumbai, India.
Company Details
Key Leadership
Latest News
GENPHARMA Stock Details & Analysis
Key Financial Metrics
Growth & Valuation
Frequently Asked Questions
What is the current price of Genpharmasec Ltd (GENPHARMA)?
As of 29 Jan 2026, 10:33 am IST, Genpharmasec Ltd (GENPHARMA) is currently trading at ₹1.16. The stock has a market capitalization of ₹81.95 (Cr).
Is GENPHARMA share price Overvalued or Undervalued?
GENPHARMA is currently trading at a P/E ratio of 149.01x, compared to the industry average of 35.45x. Based on this relative valuation, the stock appears to be Overvalued against its sector peers.
What factors affect the Genpharmasec Ltd share price?
Key factors influencing GENPHARMA's price include its quarterly earnings growth (Sales Growth: 441.29%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Genpharmasec Ltd a good stock for long-term investment?
Genpharmasec Ltd shows a 5-year Profit Growth of N/A% and an ROE of 1.90%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.17 before investing.
How does Genpharmasec Ltd compare with its industry peers?
Genpharmasec Ltd competes with major peers in the Trading & Distributors. Investors should compare GENPHARMA's P/E of 149.01x and ROE of 1.90% against the industry averages to determine its competitive standing.
What is the P/E ratio of GENPHARMA and what does it mean?
GENPHARMA has a P/E ratio of 149.01x compared to the industry average of 35.45x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹149 for every ₹1 of annual earnings.
How is GENPHARMA performing according to Bull Run's analysis?
GENPHARMA has a Bull Run fundamental score of 11/100, which indicates concerns that require careful analysis. This comprehensive rating is based on 15+ financial parameters including profitability, growth metrics, and valuation ratios.
What sector and industry does GENPHARMA belong to?
GENPHARMA operates in the Trading & Distributors industry. This classification helps understand the competitive landscape and sector-specific trends affecting Genpharmasec Ltd.
What is Return on Equity (ROE) and why is it important for GENPHARMA?
GENPHARMA has an ROE of 1.90%, which suggests challenges in generating returns from shareholders' equity. Return on Equity measures how efficiently Genpharmasec Ltd generates profits from shareholders' equity.
How is GENPHARMA's debt-to-equity ratio and what does it indicate?
GENPHARMA has a debt-to-equity ratio of 0.17, which indicates conservative financing with low financial risk. A ratio below 1.0 generally indicates conservative financing.
What is GENPHARMA's dividend yield and is it a good dividend stock?
GENPHARMA offers a dividend yield of 0.00%, which means you receive ₹0.00 annual dividend for every ₹100 invested.
How has GENPHARMA grown over the past 5 years?
GENPHARMA has achieved 5-year growth rates of: Sales Growth N/A%, Profit Growth N/A%, and EPS Growth N/A%.
What is the promoter holding in GENPHARMA and why does it matter?
Promoters hold 29.98% of GENPHARMA shares, with 0.00% of promoter shares pledged. High promoter holding often indicates strong management confidence.
What is GENPHARMA's market capitalization category?
GENPHARMA has a market capitalization of ₹82 crores, placing it in the Small-cap category.
How volatile is GENPHARMA stock?
GENPHARMA has a beta of N/A. A beta > 1 suggests the stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is the 52-week high and low for GENPHARMA?
GENPHARMA has a 52-week high of ₹N/A and low of ₹N/A.
What is GENPHARMA's operating profit margin trend?
GENPHARMA has a 5-year average Operating Profit Margin (OPM) of N/A%, indicating the company's operational efficiency.
How is GENPHARMA's quarterly performance?
Recent quarterly performance shows YoY Sales Growth of 441.29% and YoY Profit Growth of -268.57%.
What is the institutional holding pattern in GENPHARMA?
GENPHARMA has FII holding of 0.00% and DII holding of 0.00%. Significant institutional holding often suggests professional confidence in the stock.